Pyxis Oncology (PYXS) Fundamental Analysis: Revenue, Earnings & Valuation

6.17 / 10

Outperform

Fundamentally, PYXS is rated Outperform with a 6.2/10 score. Strengths include low current‑liabilities ratio, strong interest coverage and healthy revenue‑to‑market metrics. Weaknesses lie in PB‑ROE and modest inventory turnover. Overall, the balance sheet appears constructive.

Analysis Checks(9/10)

Revenue-MV

Value-0.32

Score3/3

Weight29.68%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-14.17

Score2/3

Weight0.41%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.38%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value55.44

Score2/3

Weight1.15%

1M Return0.36%

PB-ROE

Value-0.29

Score1/3

Weight23.98%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.33

Score3/3

Weight2.60%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.44%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-14.17

Score2/3

Weight0.16%

1M Return0.05%

Cost of sales ratio (%)

Value17.23

Score2/3

Weight-3.25%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight52.10%

1M Return11.61%

Is PYXS undervalued or overvalued?

PYXS scores 6.17/10 on fundamentals and holds a Discounted valuation at present. Backed by its -91.43% ROE, -574.55% net margin, -1.17 P/E ratio, 1.74 P/B ratio, and 3.03% earnings growth, these metrics solidify its Outperform investment rating.